Pharma BD Deal Intelligence
Cephalon executes biologics diversification thesis with $250M Ception buyout following positive reslizumab Phase 2 in eosinophilic asthma.
Cephalon announced completion of the Ception acquisition, with Ception becoming a wholly-owned subsidiary and Cephalon purchasing all outstanding capital stock…
Reslizumab journey from Schering-Plough → Ception → Cephalon ($250M, 2010) → Teva ($6.8B, 2011) → FDA approval as Cinqair in March 2016 for severe eosinophilic…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cephalon exercised option to acquire Ception for $250M following positive Phase 2 eosinophilic asthma data on reslizumab.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Ception Therapeutics (this deal) | 2010 | $250M | 23 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2010 deals · Cephalon Inc. deals · Respiratory deals